Overall, these results demonstrate that pretreatment with apigenin sensitizes primary patient-derived lung cancer cells and established NSCLC cell lines to TRAIL-induced caspase-3-dependent apoptosis without affecting the viability of nontransformed cells or primary patient-derived nontumor lung epithelial cells. The gene discussed is CASP3; the disease is lung carcinoma.